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Background: H19 is a paternally imprinted gene that has been shown to be highly expressed in the trophoblast
tissue. Results from previous studies have initiated a debate as to whether noncoding RNA H19 acts as a tumor
suppressor or as a tumor promotor in trophoblast tissue. In the present study, we developed lentiviral vectors
expressing H19-specific small interfering RNA (siRNA) to specifically block the expression of H19 in the human
choriocarcinoma cell line JAR. Using this approach, we investigated the impact of the H19 gene on the
proliferation, invasion and apoptosis of JAR cells. Moreover, we examined the effect of H19 knockdown on the
expression of insulin-like growth factor 2 (IGF2), hairy and enhancer of split homologue-1 (HES-1) and dual-specific
phosphatase 5 (DUSP5) genes.
Results: H19 knockdown inhibited apoptosis and proliferation of JAR cells, but had no significant impact on cell
invasion. In addition, H19 knockdown resulted in significant upregulation of HES-1 and DUSP5 expression, but not
IGF2 expression in JAR cells.
Conclusions: The finding that H19 downregulation could simultaneously inhibit proliferation and apoptosis of JAR
cells highlights a putative dual function for H19 in choriocarcinoma and may explain the debate on whether H19
acts as a tumor suppressor or a tumor promotor in trophoblast tissue. Furthermore, upregulation of HES-1 and
DUSP5 may mediate H19 downregulation-induced suppression of proliferation and apoptosis of JAR cells.
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H19 is a paternally imprinted gene encoding a noncoding
RNA [1]. As one of the first imprinted genes discovered,
H19 was initially identified as a tumor suppressor because
embryo-derived tumor cells overexpressing H19 exhibited
growth retardation, morphological changes and abrogated
clonogenicity in soft agar, as well as suppressed tumori-
genicity in nude mice [2]. Downregulation of H19 gene ex-
pression was identified as an early event in the formation
of several tumor types [3-8]. Recently it was demonstrated* Correspondence: chenming1971@yahoo.com; lililiyuyu@sina.com
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reproduction in any medium, provided the orthat mice lacking H19 showed an overgrowth phenotype,
while transgenic mice overexpressing H19 showed postna-
tal growth reduction [9].
In contrast, overexpression or loss of imprinting (LOI) of
H19 has been observed in a wide variety of tumors, inclu-
ding bladder carcinoma [10,11], epithelial ovarian cancer
[12], esophageal cancer [13], lung cancer [14], breast adeno-
carcinoma [15,16], endometrial cancer [17], and invasive
cervical carcinoma [18]. H19 knockdown significantly
decreased the clonogenicity and anchorage-independent
growth property of several breast and lung cancer cell
lines [19]. A link between H19 and several tumorigenesis-
related genes, such as c-Myc [19], thioredoxin [20] and
E2F1 [21], has been well established. Thus, it remains con-
troversial whether H19 functions as a tumor promotor or
a tumor suppressor, and it is possible that H19 playsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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H19 is highly expressed in trophoblast tissue, predomin-
antly but not exclusively from the maternal allele [22,23].
Complete hydatidiform moles (CHM) showed high-level
expression of H19 from the paternal allele, while chorio-
carcinomas developing from CHMs had reduced numbers
of H19-positive cells [23]. H19 downregulation was also
observed in gestational trophoblastic tumors [24]. These
observations appear to support the notion that H19 func-
tions as a tumor suppressor in trophoblast tissue. How-
ever, Ariel I et al. found that H19 expression was found to
be abundant, in a decreasing order, in the intermediate
trophoblast (villous and interstitial), the cytotrophoblast,
and the syncytiotrophoblast. And prominent expression of
H19 was found in placental site trophoblastic tumor and
gestational choriocarcinoma [25]. After choriocarcinoma-
derived JEG-3 cells were subcutaneously injected into
nude mice, a five-fold increase in H19 RNA level was
detected in the resulting tumors, and cells highly express-
ing H19 were more tumorigenic [26]. Therefore, the exact
role of H19 in the trophoblast is yet undetermined.
In previous studies, we demonstrated that DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine could de-
methylate the promoter region of the H19 gene, upregulate
the expression of H19 transcript, and reduce the proliferation,
migration and invasion properties of choriocarcinoma-
derived JEG-3 cells [27,28]. As the demethylating effects of 5-
aza-2′-deoxycytidine are unspecific, other genes may be
demethylated in tandem and complicate the biological effects.
To further clarify our understanding of the function of the
H19 gene in choriocarcinoma, we developed lentiviral vectors
expressing H19-specific small interfering RNA (siRNA) for
use in human choriocarcinoma cells. Considering that the
human choriocarcinoma cell line JAR is more easily infected
by lentiviruses than the cell line JEG-3 (our unpublished ob-
servation), JAR cells were used in the present study. Using
the siRNA technology, we investigated the impact of H19
knockdown on the proliferation, invasion, and apoptosis of
JAR cells. Furthermore, we examined the effects of H19
knockdown on the expression of the insulin-like growth fac-
tor 2 (IGF2), hairy and enhancer of split homologue-1 (HES-
1), and dual-specific phosphatase 5 (DUSP5) genes, which
were chosen based on the previous evidence that H19 is a
negative regulator of IGF2 [29] and our unpublished observa-
tion that the expression of HES-1 and DUSP5 genes was al-
tered in JEG-3 cells transfected with a eukaryotic expression
vector carrying the full-length H19 cDNA.
Methods
Cell culture
Human choriocarcinoma cell line JAR was purchased
from American Type Culture Collection (USA). After
thawing, cells were allowed to grow in Dulbecco’smodified Eagle’s medium/Ham’s nutrient mixture F12
(DMEM/F12; Gibco-BRL, USA) medium supplemented
with 10% fetal bovine serum (Gibco-BRL, USA) at 37°C
in a humidified atmosphere containing 5% CO2. After
three passages, cells were used for viral infection.
Construction and screening of lentiviral vectors harboring
H19-specific siRNA
The following siRNA target sequences in the human H19
gene (GenBank accession No. NR_002196) were selected:
TARGET1, GCCTTCAAGCATTCCATTA; TARGET2,
GGAGAGTTAGCAAAGGTGA; TARGET3, CGTGACA
AGCAGGACATGA; and TARGET4, GAGGAACCAGA
CCTCATCA. Four pairs of complementary oligonucleo-
tides were then designed (Additional file 1: Table S1). The
stem-loop oligonucleotides were synthesized and cloned
into a lentivirus-based vector carrying the green fluores-
cent protein (GFP) gene (pGCSIL-GFP, Genechem, Shang-
hai, China). A universal sequence (PSC-NC: TTCTCCG
AACGTGTCACGT) was used as a negative control for
RNA interference. Lentiviral particles were prepared as
previously described [30].
The four siRNA-carrying lentiviral vector constructs
were used to infect JAR cells at a multiplicity of infec-
tion (MOI) of 20 (low MOI) and 40 (high MOI). Three
days after infection, GFP expression was detected to cal-
culate the infection efficiency. Five days after infection,
cells were harvested. Real-time reverse transcription-
polymerase chain reaction (RT-PCR) was performed to
determine H19 knockdown efficiency and screen for the
siRNA with the highest knockdown efficiency which was
then used for subsequent experiments.
RNA isolation, reverse transcription and quantitative PCR
Total RNA isolation using Trizol Reagent (Invitrogen,
USA) and reverse transcription using Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Promega,
USA) were carried out according to the manufacturer’s in-
structions. Quantitative PCR was performed in a final vol-
ume of 20 μl containing 1 μl cDNA, 0.5 μl primers (2.5
μM) and 10 μl SYBR premix exTaq (TaKaRa, Dalian,
China). The cycling conditions were: 95°C for 15 min; 40
cycles of 95°C for 5 s and 60°C for 30 s; and one cycle of
95°C for 60 s, 55°C for 60 s and 95°C for 60 s. The se-
quences of primers used in real-time RT-PCR were as fol-
lows: forward 5′-TCCCAGAACCCACAACATGAA-3′
and reverse 5′-TTCACCTTCCAGAGCCGATTC-3′ for
H19 (150 bp); forward 5′-TCCTCACCTCGCTACTCG-3′
and reverse 5′-ACATCCACGCAACACTCAG-3′ for
DUSP5 (106 bp); forward 5′-GAGAGGCGGCTAAGG
TGTTTG-3′ and reverse 5′-CTGGTGTAGACGGG
GATGAC-3′ for HES-1 (121 bp); forward 5′-CCTCC
AGTTCGTCTGTGGG-3′ and reverse 5′-CACGTCCCT
CTCGGACTTG-3′ for IGF2 (163 bp); and forward
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5′-AGGGGCCGGACTCGTCATACT -3′ for beta-actin
(202 bp). Data analysis was performed using the 2-ΔΔCt
method. The experiment was independently repeated
three times.
Cell cycle analysis
Cells were seeded onto six-well plates and cultured.
Upon reaching 80% confluence, cells were released by
digestion with trypsin and harvested. After centrifuga-
tion, the cell pellet was washed twice with pre-cooled
phosphate buffered saline (PBS) and fixed with pre-
cooled 70% ethanol. Then, cells were resuspended in
PBS, filtered through a 400-mesh sieve, and stained with
propidium iodide (PI, 50 μg/mL, 100 μg/mL RNase in
PBS) at 37°C for 30 min. The cell cycle was then deter-
mined by flow cytometry as previously described [31].
Apoptosis assay
Apoptosis was detected using the ApoScreen Annexin V
Apoptosis Kit (SouthernBiotech, USA) according to the
manufacturer’s instructions. In addition, one more group of
cells was incubated with 30 μg/ml diaminedichloroplatinum
(DDP) for 16 hours and subjected to apoptosis assay. The
experiment was independently repeated three times.
Methyl thiazolyl tetrazolium (MTT) assay
Cells were seeded in sextuplicate for each condition in 96-
well plates at a density of 2×104/mL in 100 μl per well. After
24 hours of culture, medium was replaced. Cells were then
further cultured in this manner for 1–6 days. Four hours be-
fore the termination of culture, MTT (5 mg/mL; Sigma,
USA) was added at a volume of 10 μL per well. Afterwards,
the entire supernatant was discarded and dimethyl sulfoxide
(DMSO) was added at a volume of 100 μL per well and in-
cubated in an air bath shaker at 37°C for 10 min. The ab-
sorbance at 570 nm of each well was determined using the
1420 Multilabel Counter (PerkinElmer, USA). The experi-
ment was independently repeated three times.
Cell invasion assay
The cell invasion assay was performed using a commer-
cial kit (Chemicon, Canada), according to the manufac-
turer’s instructions. The CHEMICON Cell Invasion
Assay is performed in an Invasion Chamber, a 24-well
tissue culture plate with 12 cell culture inserts. The in-
serts contain an 8 μm pore size polycarbonate membrane,
over which a thin layer of ECMatrixTM is dried. The
ECMatrixTM layer serves as an in vitro reconstituted
basement membrane and occludes the membrane pores,
blocking non-invasive cells from migrating through. Inva-
sive cells, on the other hand, migrate through the ECM
layer and cling to the bottom of the polycarbonate mem-
brane. Before JAR cells were plated at a density of 1 × 104cells in each insert, 300 μL of warm serum free media were
added to the interior of the inserts to rehydrate the ECM
layer for 1–2 hours at room temperature. Cells were incu-
bated at 37°C in 5% CO2 for 72 h. A cotton-tipped swab
was used to gently remove non-invading cells as well as
the ECMatrix gel from the interior of the inserts. Five
hundred microliters of staining solution were added to
the unoccupied wells of the plate. Invasive cells on
lower surface of the membrane were stained by dipping
inserts in the staining solution for 20 minutes. Inserts
were dipped in a beaker of water several times to rinse
and air dried. Stained cells were dissolved in 10% acetic
acid and OD at 560 nm was detected by colorimetric
reading. Each assay was performed in triplicate and re-
peated three times.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 soft-
ware package (SPSS Inc, Chicago, IL, USA). Numerical
data are expressed as mean ± standard deviation. Mul-
tiple means were compared using analysis of variance
and the Tukey post hoc test, while two means were
compared using Student’s t-test. A P value of less than
0.05 was considered statistically significant.
Results
Selection of the lentiviral vector harboring siRNA with the
highest knockdown efficiency
The four lentiviral constructs harboring different siRNAs
(KD1, KD2, KD3 and KD4) were used to infect JAR cells.
In parallel, a negative control (NC) was run. The infec-
tion efficiencies of these lentiviral vectors were all above
80% as revealed by fluorescence microscopy (Figure 1A).
Real-time RT-PCR assay showed that all four constructs,
whether they were used at a high or low MOI, could sig-
nificantly downregulate H19 gene expression in JAR cells
(Figure 1B, C). The highest knockdown efficiency was
achieved using KD3 (low MOI: 93% relative to the NC
group; high MOI: 95%), which was subsequently desig-
nated as H19-RNAi-LV-3.
H19 Knockdown inhibited the proliferation of JAR cells
The percentage of cells in G1 phase was significantly
higher in the H19 knockdown group than in the NC
group (P < 0.01), while the percentages of cells in G2/M
phase and S phase respectively showed no significant
changes between the two groups (Figure 2A). The MTT
assay showed that cell proliferation was significantly
inhibited in the H19 knockdown group as compared to
that in the NC group (P < 0.01) (Figure 2B).
H19 Knockdown inhibited apoptosis of JAR cells
As shown in Figure 3, H19 knockdown significantly in-
creased the percentage of normal cells but decreased the
Figure 1 Selection of the lentiviral vector harboring siRNA with the highest knockdown efficiency. A, Fluorescence microscopy
examination of the infection efficiencies of different lentiviral vectors in JAR cells (magnification 200 ×). a. JAR cells infected with lentiviral
particles harboring a non-targeting control siRNA (NC group) in the light microscope; b. JAR cells of NC group in the fluorescence microscope; c.
Fusion image of the top two images; d. JAR cells infected with KD3-harboring lentiviral particles (KD group)at a low MOI in the light microscope;
e. JAR cells of KD group at a low MOI in the fluorescence microscope; f. Fusion image of the top two images; g. JAR cells infected with KD3-
harboring lentiviral particles at a high MOI in the light microscope; h. JAR cells of KD group at a high MOI in the fluorescence microscope. i.
Fusion image of the top two images. The fluorescence expression in cells infected with KD1, KD2 and KD4 was similar to that in cells infected
with KD3. The infection efficiencies of these lentiviral vectors were about to be above 80%. B, Relative levels of H19 in JAR cells infected with
different groups of lentiviral particles at a low MOI. C, Relative levels of H19 in JAR cells infected with different groups of lentiviral particles at a
high MOI. Compared to the NC group, H19 expression was significantly downregulated in JAR cells infected with different groups of lentiviral
particles, at either a low or high MOI. Beta-actin was used to normalize the PCR data. The highest knockdown efficiency was achieved using KD3-
harboring lentiviral particles.
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Figure 2 Effect of H19 knockdown on the growth of JAR cells. A, Comparison of the percentages of cells in G1, G2/M and S phase between
NC and KD groups. The percentage of cells in G1 phase was significantly higher in the KD group than in the NC group, while the percentages of
cells in G2/M phase and S phase respectively showed no significant changes between the two groups. B, Growth curves of cells in each group.
MTT analysis showed that H19 knockdown significantly inhibited cell proliferation (n = 18). ** denotes P < 0.01.
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negative control group (85.70% ± 0.41% vs. 60.4% ± 0.70%
and 8.46% ± 0.37% vs. 30.74% ± 1.45%, respectively; Ps <
0.01 for both). After incubation with diaminedichlo-
roplatinum (an apoptosis inducer) for 16 hours, the per-
centage of normal cells was still significantly higher in the
H19 knockdown group than in the NC group (80.70% ±
1.88% vs. 55.20% ± 0.98%, P < 0.01), while the percentage
of early apoptotic cells was still significantly lower in the
H19 knockdown group than in the NC group (7.80% ±
2.39% vs. 30.00% ± 0.46%, P < 0.01).
H19 Knockdown does not alter the invasion of JAR cells
To determine if H19 knockdown was able to affect the in-
vasion properties of JAR cells, the cell invasion assay was
performed. The invasion rate of cells in the H19 knock-
down group and the NC group were 68.85% ± 3.04% and
79.50% ± 5.52%, respectively. H19 knockdown had no sig-
nificant impact on the invasion rate of JAR cells. The re-
sult was shown in Additional file 1: Figure S1.
H19 Knockdown upregulated HES-1 and DUSP5
expression but not IGF2 expression
To gain insight into how H19 knockdown alters the
phenotype of human choriocarcinoma cells, we exam-
ined the expression of IGF2, HES-1 and DUSP5 mRNAs
by real-time RT-PCR. The results showed that, com-
pared with the negative control group, H19 knockdown
significantly upregulated the expression of HES-1 and
DUSP5 mRNAs (1.24 ± 0.06 vs. 1.01 ± 0.14 and 2.81 ±
0.30 vs. 1.00 ± 0.05; P < 0.05 and 0.01, respectively), but
had no significant impact on the expression of IGF2
mRNA (1.22 ± 0.09 vs. 1.02 ± 0.21; P > 0.05, Figure 4).
The Ct values were shown in Additional file 1: Table S2.Discussion
Using a lentiviral vector harboring H19-specific siRNA,
the expression of H19 in JAR cells was specifically
downregulated. We showed that the invasion of JAR cells
was not affected in response to H19 downregulation,
which is inconsistent with our previous studies indicating
that 5-aza-2′-deoxycytidine-mediated H19 upregulation
could reduce the invasion capacity of JEG-3 cells [27,28].
This may be due to unspecific demethylating effects of 5-
aza-2′-deoxycytidine or differences among the cell types
studied. Furthermore, we also demonstrated that H19
knockdown inhibited the apoptosis and proliferation prop-
erties of JAR cells. The results of the present study indi-
cate that H19 exerts both tumor-promoting and tumor-
suppressing effects in choriocarcinoma cells, at least in
part, by regulating cell proliferation and apoptosis.
It has been hypothesized for many years that a poten-
tial tumor suppressor gene is present at chromosome
11p15.5 where H19 is located, because a loss of hetero-
zygosity at this locus is observed in certain embryonal
tumors [2]. Subsequent experiments implicated H19
may function as a tumor suppressor [2,8]. However,
other studies provided conflicting evidence that sup-
ported the idea that H19 RNA harbors oncogenic prop-
erties [10-20]. Similar observations have been made in
trophoblast tissue; some studies revealed that H19 has
tumor-suppressing activity [23,24], while others sug-
gested that it has tumor-promoting activity [26]. There-
fore, H19 may play differential roles under different
physiologic conditions. In the present study, we demon-
strated that H19 knockdown could simultaneously in-
hibit the proliferation and apoptosis of JAR cells,
suggesting that H19 expression may have both
proliferation-inducing and apoptosis-inducing activity in
Figure 3 Effect of H19 knockdown on the apoptosis of JAR cells. A. Comparison of the percentages of normal cells and early apoptotic cells
between the NC group and the KD group. H19 knockdown significantly increased the percentage of normal cells but decreased the percentage
of early apoptotic cells when compared with the NC group; B. Flow cytometric analysis of JAR cells in the NC group and the KD group; C.
Comparison of the percentages of normal cells and early apoptotic cells between the two groups with DDP treatment. H19 knockdown also
significantly increased the percentage of normal cells but decreased the percentage of early apoptotic cells when compared with the NC-DDP
group; D. Flow cytometric analysis of JAR cells in the NC-DDP group and the KD-DDP group. NC-DDP is the negative control vector-harboring
cells incubated with DDP; KD-DDP, H19-RNAi-LV-3-infected cells incubated with DDP. ** denotes P < 0.01.
Figure 4 Effect of H19 knockdown on the expression of IGF2,
HES-1 and DUSP5 mRNAs in JAR cells. H19 knockdown
significantly upregulated the expression of HES-1 and DUSP5 mRNAs,
but had no significant impact on the expression of IGF2 mRNA. KD,
H19 knockdown group. * denotes P < 0.05 and ** denotes P < 0.01.
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in tumorigenesis is the loss of equilibrium between cell
proliferation and cell death [32]. Thus, our observation
that H19 can simultaneously induce proliferation and
apoptosis highlights a putative dual role of H19 in
choriocarcinoma cell lines and may explain the debate
over whether H19 is a tumor suppressor or a tumor pro-
motor in trophoblast tissue. Shoshani O et al. discovered
that direct knockdown of H19 expression in diploid
tumorigenic mouse mesenchymal stromal cells(MSCs)
resulted in acquisition of polyploid cell traits. And artifi-
cial tetraploidization of diploid MSCs reduces tumori-
genic potential in conjunction with suppression of H19
expression. This establishs a link between H19 expres-
sion and cell ploidy. Poluploidization might either have a
cancer promoting or a cancer-preventing effect as is the
case in aneuploidy [33]. Then, further experiments
should determine whether the inhibition of proliferation
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polyploidy of trophoblast cells. However, since the hu-
man choriocarcinoma cell line JAR may already have a
different H19 gene regulatory pattern from normal tro-
phoblasts, the extrapolation of results from JAR cells to
the normal trophoblast must be cautious. Further stud-
ies in normal trophoblast cells should be done to address
this issue.
Like H19, IGF2 is an imprinted gene and the two are
closely linked. However, while H19 is expressed from the
maternal allele, IGF2 is transcribed from the paternal al-
lele in most tissues [34]. A growing body of evidence has
indicated that H19 RNA is a negative regulator of IGF2.
Gabory et al. [9] demonstrated that H19 transgenic or
knockout mice developed abnormal phenotypes due to
alterations in IGF2 mRNA levels. Esquiliano et al. [35]
found that targeted disruption of the H19 gene in mice
induced the placental phenotype via upregulation of
IGF2 expression. In the present study, we have demon-
strated that H19 knockdown had no significant impact
on the expression of IGF2 mRNA. Nevertheless, this re-
sult is not too surprising because numerous studies have
not been able to provide a consistent relationship be-
tween the expression levels and imprinting status of H19
and IGF2 in all tissues. Adam et al. [36] discovered that H19
showed biallelic expression in extravillous cytotrophoblasts,
while IGF2 showed monoallelic expression. Lustig-Yariv
et al. [37] showed that H19 and IGF-2 RNA levels dif-
fered greatly among different JAR or JEG-3 clones. More-
over, we also found that both H19 and IGF-2 RNAs were
highly expressed in normal term placenta and JEG-3 cells,
and H19 overexpression did not alter IGF2 expression in
JEG-3 cells (unpublished data). Therefore, these data sug-
gest that IGF2 may not be involved in H19 downregulation-
mediated inhibition of proliferation and apoptosis of JAR
cells.
Our results did show that H19 knockdown signifi-
cantly upregulated expression of the HES-1 gene in JAR
cells. HES-1 gene is an important effector of the Notch
pathway that has been implicated in regulating the pro-
liferation, differentiation and apoptosis in multiple
tumor cell types. Kunnimalaiyaan et al. [38] found that
increased HES-1 expression suppressed the proliferation
of carcinoid tumor cells. Nefedova et al. [39] demon-
strated that overexpression of HES-1 abrogated gamma-
secretase inhibitor-induced apoptosis in multiple myeloma
cells. Importantly, we also found that H19 overexpression
could downregulate the expression of HES-1 in JEG-3 cells
(about 2.27 fold) (unpublished data). Thus, we speculated
that HES-1 may mediate H19 downregulation-induced
suppression of proliferation and apoptosis of JAR cells.
Although it remains unclear how H19 knockdown
upregulates HES-1 expression in JAR cells, the recent
finding that H19 can negatively regulate an imprintedgene network may provide some clues to the mecha-
nisms of regulation of HES-1 expression by H19 [9].
Furthermore, we demonstrated that H19 knockdown
could also significantly upregulate the expression of
DUSP5 gene in JAR cells. The DUSP5 gene encodes a
mitogen-activated protein kinase phosphatase (MKP).
It has been shown that extracellular signal regulated
kinase 2 (ERK2) is a specific substrate of DUSP5 [40].
As ERK2 plays an important role in regulating cell
proliferation and apoptosis, it is reasonable to surmise
that DUSP5 may also be involved in such processes.
Importantly, we also found that H19 overexpression
could downregulate the expression of DUSP5 in JEG-3
cells (about 2.63 fold) (unpublished data). Therefore,
DUSP5 may also be involved in H19 downregulation-
induced suppression of proliferation and apoptosis of
JAR cells.
Conclusions
The present study provides evidence that H19 knock-
down does not alter invasion but inhibits proliferation
and apoptosis of JAR cells. The observation that H19
downregulation simultaneously suppresses proliferation
and apoptosis of JAR cells suggests a putative dual func-
tionality of H19 in choriocarcinoma cell lines and may
explain the debate over whether H19 is a tumor suppres-
sor or a tumor promotor in trophoblast tissue. More-
over, we also found that H19 knockdown upregulates
the expression of the HES-1 and DUSP5 genes but not
of the IGF-2 gene, suggesting that HES-1 and DUSP5
may mediate H19 downregulation-induced suppression
of proliferation and apoptosis of JAR cells.
Additional file
Additional file 1: Table S1. The structure of siRNAs in lentiviral
vectors. Table S2 The Ct values from quantitative PCR reactions. Figure
S1: Effect of H19 knockdown on the invasion of JAR cells. The invasion
rate of cells in the H19 knockdown group and the NC group were
68.85% ± 3.04% and 79.50% ± 5.52%, respectively. H19 knockdown had
no significant impact on the invasion rate of JAR cells.
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